Potential of interferon-alpha in solid tumours: part 2

Area of Science:

• Oncology
• Immunotherapy

Background:

• Recombinant interferon-alpha (rIFNalpha) is a biologic agent with potential applications in solid tumor treatment.
• Its efficacy and optimal use vary across different cancer types.

Purpose of the Study:

• To review the current evidence on the use of rIFNalpha in various solid tumors.
• To identify specific malignancies where rIFNalpha shows therapeutic potential and areas requiring further investigation.

Main Methods:

• Review of existing literature on rIFNalpha in superficial bladder cancer, Kaposi's sarcoma, head and neck cancer, gastrointestinal cancers, lung cancer, mesothelioma, ovarian, breast, and cervical cancers.
• Analysis of treatment outcomes, combination therapies, and patient selection criteria.

Main Results:

• Intravesical rIFNalpha is promising for BCG-refractory superficial bladder cancer.
• rIFNalpha is active in HIV-associated Kaposi's sarcoma, particularly in specific patient groups.
• Encouraging results seen in chemoprevention of head and neck and hepatocellular cancers.
• rIFNalpha shows potential as second-line treatment for neuroendocrine tumors and in minimal residual disease for ovarian cancer.
• Limited or no recommended use in head and neck squamous cell cancers, GI, lung cancers, or mesothelioma.
• Pegylated interferon-alpha (peginterferon-alpha) offers potential advantages.

Conclusions:

• rIFNalpha has a defined role in specific solid tumors like superficial bladder cancer and Kaposi's sarcoma.
• Further randomized trials are essential to confirm efficacy in ovarian, cervical cancers, and neuroendocrine tumors.
• Understanding the biological mechanisms of response is crucial for targeted therapy selection.